FTH vs APMD
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
FTH · Faeth Therapeutics$22.05 ▲ 10.69%
APMD · Apnimed$15.10 ▲ 6.64%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- FTH -19.1%
- APMD -39.6%
Head to head
| Metric | FTH | APMD |
|---|---|---|
| Price | $22.05 | $15.10 |
| Change today | ▲ 10.69% | ▲ 6.64% |
| Market cap | $569.86M | $628.62M |
| Return, 3 months | -22.8% | -46.0% |
| Return, year to date | +106.7% | – |
| Return, 1 year | +142.3% | – |
| P/E (TTM) | -1.0 | 3.9 |
| P/B | 3.5 | -3.6 |
| P/E percentile vs own 5y | 96th | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -29.4% |
| Net profit growth (YoY) | -224.3% | +281.3% |
| Gross margin | – | 93.9% |
| Operating margin | – | 30.9% |
| Net margin | – | 252.6% |
| Return on equity | -195.3% | – |
| Analyst target vs. price | +161.2% | +233.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 50 | 35 |
| 30-day volatility | 96.9% | 91.5% |
| Max drawdown, 1 year | -69.2% | -56.5% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- APMD is the largest of the group by market value.
- FTH carries the lowest trailing P/E.
- APMD has been the calmest stock over the last 30 days.